Product Description
Mechanisms of Action: RR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chiron
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer|Esophageal Cancer|Adenocarcinoma
Phase 1: Mucositis|Leukemia, Plasma Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00061620 |
ID01-168 | P1 |
Completed |
Mucositis|Leukemia, Plasma Cell |
2004-02-12 |
2019-03-21 |
Treatments |
|
NCT00051688 |
TEZ101 | P2 |
Terminated |
Colorectal Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00054873 |
TEZ001 | P2 |
Completed |
Esophageal Cancer|Adenocarcinoma |
None |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|